## DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

		My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claime and for which a patent is sought on the invention entitled:					
		The Use of Saccharomyces cerevisiae erg4 Mutants For Expressing Mammalian Glucose Transporters					
		and the specification of wh (check one)	nich 🛚	was filed on and was amended of was described and of	Aventis Docket No. <b>DEAV2002/0065USNP)</b> as U.S. Application Number n (if applicable). claimed in PCT Int'l Application Number filed on ended under PCT Article 19 on (if any).		
		I/We hereby state that I/We have reviewed and understand the contents of the above identified specification including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.					
Σ	3	I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:					
	oreign riority:	10242763.1 Number	German Country	Dy	14 September 2002 Day/Month/Year Filed		
F	rior oreign .ppln(s):	Number	Country		Day/Month/Year Filed		
	⅓	I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:					
		60/455,340 Number	March 1 Filing Da	17, 2003 te			
C		I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.					
		Application Serial No.	Filing Da	te	Status (Patented, Pending)		
and	d belief a	re believed to be true; and	further tha	t these statements w	edge are true and that all statements made on informatio ere made with the knowledge that willful false statement under Title 18, United States code §1001, and that suc any patent issued thereon.		
lnv	entors(s)	: X Additional names	and signa	tures are attached.			
<b>1.</b> F	Full name:	Guenter Mueller		2.	Full name: Silke Dlugai		
Signature:					nature:		
Date:					:		
Country of Citizenship: Germany					ntry of Citizenship: Germany		
Residence: Sulzbach am Taunus, Germany (City and State/City and Country only)					idence: Dusseldorf, Germany (City and State/City and Country only)		
P. C	). Address:	Im Haindell 1b		P. C	Address: Burscheiderstrasse 40		
		Sulzhach am Taunus C		70.40	Dusseldorf, Germany 40591		

3. Full name: Doerthe Voss	4. Full name: Eckhard B les	
Signature:		
Date:	Signature:	
Country of Citizenship: Germany		
Residence: Dusseld rf, Germany (City and State/City and Country only)		
P. O. Address: Kampstrasse 50		
Dusseldorf, Germany 40591	P. O. Address: Rontgenweg 5	
	Dusseldorf, Germany 40591	

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3800
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0065USNP